Vasoactive Intestinal Peptide (VIP)

1. Quick Facts

Category: Neuropeptide / Immune-Modulating Peptide

Risk Level: Moderate/High

Research Status: Moderate Human Research

Administration: Intranasal or Subcutaneous

Typical Frequency: 1–4x Daily Intranasal / 1–3x Daily SubQ

Estimated Half-Life: Very Short Plasma Half-Life (Minutes)

Primary Research Interest: Inflammation / Respiratory Support / Immune Signaling

Important Disclaimer

This material is provided strictly for educational and informational purposes related to peptide research and neuroimmune compounds. Vasoactive Intestinal Peptide (VIP) is a biologically active signaling peptide capable of influencing inflammatory, vascular, neurological, respiratory, and immune-modulating pathways. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.

2. Summary

Vasoactive Intestinal Peptide (VIP) is a naturally occurring neuroimmune signaling peptide researched for its potential effects on inflammation, respiratory pathways, immune modulation, autonomic balance, and vascular signaling.

Research interest in VIP commonly centers around inflammatory regulation, respiratory support pathways, immune-system balance, autonomic function, and neurological signaling.

What People Commonly Claim

Mold illness recovery
CIRS improvement
Reduced inflammation
Better breathing
Improved energy
Neurological recovery
Immune-system normalization

What the Literature Actually Shows

VIP is a naturally occurring neuropeptide involved in immune, neurological, respiratory, and vascular signaling.
Research demonstrates anti-inflammatory and immune-modulating effects.
VIP influences cytokine activity, smooth-muscle relaxation, and autonomic regulation.
Clinical investigation has occurred in respiratory disease, inflammatory disorders, pulmonary hypertension, and immune dysfunction.
Many modern mold-illness and CIRS applications are based on emerging clinical frameworks rather than large randomized clinical trials.

3. Intranasal Reconstitution Guide

Vial Size: 5 mg
Dilutant Type: BAC Water
Total Dilutant Amount: 30 mL
Final Concentration: 0.167 mg/mL

Mixing Instructions:
• Reconstitute the vial with 3 mL BAC water
• Transfer the entire contents into a 30 mL nasal spray bottle
• Add an additional 27 mL BAC water

Approximate spray delivery:
• ~29 mcg per spray
• Spray bottle delivery volume assumed to be ~0.175 mL per spray

4. Intranasal Route & Protocol

VIP is commonly researched as an intranasal peptide for respiratory, inflammatory, immune-modulating, and neurological applications.

Primary Route: Intranasal
Typical Delivered Amount: 1–2 sprays per nostril
Frequency: 1–4 times daily
Cycle Length: Indefinite / PRN for illness-related research
Special Notes: VIP is commonly researched for respiratory, inflammatory, immune-modulating, and mold-related illness applications, particularly in protocols focused on chronic inflammatory response syndromes. Because VIP may strongly influence vasodilation and autonomic signaling, some individuals report temporary flushing, lightheadedness, headaches, or changes in blood-pressure sensitivity. Intranasal delivery is generally preferred within the experimental community because it is less invasive and may provide more direct respiratory and neurological exposure pathways. Researchers commonly emphasize beginning with conservative dosing because some individuals appear unusually sensitive to VIP-related signaling effects.

5. Subcutaneous Reconstitution Guide

Vial Size: 5 mg
Dilutant Type: BAC Water
Amount of Dilutant Added: 2.5 mL
Final Concentration: 2.00 mg/mL

At this concentration:
• 10 mcg = 0.005 mL (0.5 units)
• 100 mcg = 0.050 mL (5.0 units)

*Different vial sizes may limit reconstitution volume. If your product differs from the specifications listed here, please use the Peptide Calculator to calculate custom concentrations and dosing protocols.

6. Subcutaneous Route & Protocol

VIP is also researched as a systemic subcutaneous injectable peptide for broader immune and inflammatory signaling applications.

Primary Route: SubQ Injection
Typical Delivered Amount: 10–100 mcg per dose
Frequency: 1–3 times daily
Cycle Length: Indefinite / PRN for illness-related research
Special Notes: Subcutaneous VIP is generally discussed as producing more systemic whole-body effects compared with intranasal administration and may therefore increase the likelihood of vasodilatory side effects such as flushing, dizziness, rapid heartbeat, or transient blood-pressure changes. Some experimental users report that SubQ administration feels significantly stronger even at relatively low doses, making conservative dose escalation especially important. Compared with intranasal delivery, subcutaneous administration is typically considered less targeted toward respiratory pathways but potentially more systemically active.

7. Mechanism of Action

VIP functions as a broad neuroimmune signaling peptide capable of influencing inflammatory regulation, vascular tone, autonomic signaling, respiratory pathways, and immune communication.

VIP acts as a signaling molecule rather than a traditional hormone, influencing communication between immune, neurological, respiratory, and vascular systems simultaneously.

Potential downstream effects discussed in research include:

Immune-modulating signaling
Anti-inflammatory pathway interaction
Respiratory pathway support
Vasodilation signaling
Neurological-autonomic regulation
Cytokine modulation

The peptide is commonly researched for its wide-ranging regulatory effects across multiple body systems.

8. VIP and CIRS

VIP has received significant attention within chronic inflammatory response syndrome (CIRS) and mold-related illness communities.

While some clinicians report encouraging outcomes, these applications remain less extensively studied than VIP’s broader physiological roles in immune regulation, respiratory biology, and neuroimmune signaling.

Readers should recognize that much of the enthusiasm surrounding VIP in mold-related illness stems from emerging clinical frameworks rather than large randomized clinical trials.

9. Potential Benefits

Potential inflammatory-modulation support
Possible respiratory pathway support
Potential autonomic nervous system regulation
Possible immune-signaling balance support
Potential neurological support applications
Possible mold-related illness research applications

10. Potential Risks / Side Effects

Moderate/High

Flushing
Lightheadedness
Rapid heartbeat
Headaches
Blood-pressure fluctuations
Nasal irritation (intranasal use)
Injection-site irritation (SubQ use)
Potential overstimulation of autonomic signaling pathways

11. Half-Life

VIP is commonly discussed as having an extremely short plasma half-life measured in minutes.

Despite this brief circulating duration, downstream effects on immune signaling, autonomic regulation, respiratory pathways, and inflammatory mediators may persist significantly longer than measurable plasma levels.

12. Storage Information

Store refrigerated before and after reconstitution
Protect from direct light exposure
Maintain sterile handling practices during preparation
Discard solutions showing discoloration or contamination

13. Contraindications / Warnings

Severe hypotension or unstable blood pressure
Pregnancy or breastfeeding
Known hypersensitivity to peptide compounds
Use alongside multiple vasoactive compounds without supervision
Severe autonomic instability concerns

14. Further Study

15. Research References

PubMed
PubMed Central (PMC)
NIH Publications
Immunology literature
Peer-reviewed neuroimmune journals
Peer-reviewed respiratory medicine journals
Inflammation and cytokine-signaling research

16. Last Reviewed

June 2026